Compound libraries
Products
EBC main page
Search
Dyes
Impurities
Chemical probes
Contacts us
Pfizer reference compounds
Services
© 2026 Copyright Enamine
Back
Product details:
ID
CAS
1256580-46-7
Purity
95%
Alectinib is a kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability.
Properties
Name
Alectinib
Smiles
CCC=1C=C2C(=O)C3=C(NC=4C=C(C#N)C=CC34)C(C)(C)C2=CC1N5CCC(CC5)N6CCOCC6
Targets
Please log in to see this information
Target name
Target pX
Target action
doi
CH5424802 | alecensa | alectinib
No data available
The compound has purity validated by NMR and/or LCMS methods.
1 mg
$148
2 mg
$177
5 mg
$320
10 mg
$527
15 mg
$655
20 mg
$741
25 mg
$878
30 mg
$1009
35 mg
$1171
40 mg
$1299
45 mg
$1430
50 mg
$1527
75 mg
$1912
100 mg
$2352
Quantity
1
Total amount
$ 320
CH5424802 | alecensa | alectinib
No data available
The compound has purity validated by NMR and/or LCMS methods.
Target activity features
It should be emphasized that the product may be active against a larger number of targets than shown on the card. The information represented here refers to the targets with the largest value of pX or the targets with ΔpX less than 1.5 from the largest pX value.
CAS:1256589-74-8
0
